Reducing the burden of disease and death from familial hypercholesterolemia: A call to action

American Heart Journal

Volumn 168, Issue 6, 2014, Pages 807-811

  Knowles, Joshua W ^a,b   O'Brien, Emily C ^c   Greendale, Karen ^b   Wilemon, Katherine ^b   Genest, Jacques ^d   Sperling, Laurence S ^e   Neal, William A ^f   Rader, Daniel J ^g   Khoury, Muin J ^h  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FH Foundation   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WEST VIRGINIA UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ELECTRONIC MEDICAL RECORD; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HEALTH PRACTITIONER; HUMAN; ICD-10; MEDICAL SOCIETY; NETHERLANDS; NON PROFIT ORGANIZATION; NORTHERN EUROPEAN; PATIENT ADVOCACY; POPULATION; REVIEW; SCREENING; UNITED KINGDOM; UNITED STATES; COMPLICATION; DELAYED DIAGNOSIS; EUROPE; HEALTH; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; ORGANIZATION AND MANAGEMENT; PREVENTION AND CONTROL;

CORONARY ARTERY DISEASE; DELAYED DIAGNOSIS; EUROPE; GLOBAL HEALTH; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; UNITED STATES;

EID: 84912082301     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.09.001     Document Type: Editorial

References (42)

1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-3490a.
2. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S1-8.
3. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68.
4. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
5. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969;2:1380-2.
6. Stone NJ, Levy RI, Fredrickson DS, et al. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49:476-88.
7. Stitzel N, Do R, Hong-Hee W. Exome sequencing identifies rare alleles contributing to the inherited basis of early-onset myocardial infarction. Abstract presented at: American Heart Association Scientific Sessions; November 16-20, 2013; Dallas, TX. Circulation 2013;128:A14028.
8. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013;127(1):e6-245.
9. Hopkins PN, Toth PP, Ballantyne CM, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis, and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S9-S17.
10. Benn M, Watts GF, Tybjaerg-Hansen A, et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012;97:3956-64.
11. Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-20.
12. Hobbs HH, Russell DW, Brown MS, et al. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990;24:133-70.
13. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-83.
14. Youngblom E, Knowles JW. Familial hypercholesterolemia. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. Genereviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.
15. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012;223:262-8.
16. Carroll MD, Kit BK, Lacher DA, et al. Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief 2013;132:1-8.
17. No authorsExpert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128:S213-56.
18. Dixon DB, Kornblum AP, Steffen LM, et al. Implementation of lipid screening guidelines in children by primary pediatric providers. J Pediatr 2014;164:572-6.
19. Gonzalez Santos L, Underberg J. Electronic chart review of a multispecialty internal medicine practice evaluating appropriate identification of patients with familial hyperlipidemia. J Clin Lipidol 2012;5:229.
20. Haase A, Goldberg AC. Identification of people with heterozygous familial hypercholesterolemia. Curr Opin Lipidol 2012;23:282-9.
21. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
22. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008;337:a1095.
23. Alonso R, de Bobadilla JF, Méndez I, et al. Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy. Rev Esp Cardiol (Engl Ed) 2008;61:382-93.
24. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011;97:1175-81.
25. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Costeffectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands. Semin Vasc Med 2004;4:97-104.
26. DeMott K, Nherera L, Shaw EJ, et al. Clinical guidelines and evidence review for familial hypercholesterolemia: the identification and management of adults and children with familial hypercholesterolemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. 2008. [National Institute for Health and Care Excellence web site. http://www.nice.org.uk/guidance/cg71/resources/cg71-familial-hypercholesterolaemia-full-guideline3. Updated August 2008. Accessed July 2014].
27. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165-8.
28. Hadfield SG, Horara S, Starr BJ, et al. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem 2009;46:24-32.
29. Pocovi M, Civeira F, Alonso R, et al. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin Vasc Med 2004;4:67-74.
30. Kindt I, O'Brien EC, Marquess M, et al. Proceedings of the FH Foundation's inaugural Familial Hypercholesterolemia Summit: Awareness to Action; September 18-19, 2013; Annapolis, MD; 2013.. [The FH Foundation web site. http://thefhfoundation.org/media/FH-Summit-2013-Proceedings-Final-clean-March-14th.pdf. Updated September 2013. Accessed July 2014].
31. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotypephenotype relationship, and clinical outcome. Eur Heart J 2014. http://dx.doi.org/10.1093/eurheartj/ehu058.
32. No authors listedStatewide screening of fifth graders leads to identification and treatment of those with genetic predisposition to early-onset heart disease. AHRQ Health Care Innovations Exchange: Innovations and Tools to Improve Quality and Reduce Disparities web site. 2014. [http://www.innovations.ahrq.gov/content.aspx?id=3002. Updated January 15, 2014. Accessed July 7, 2014].
33. Cottrell L, John C, Murphy E, et al. Individual-, family-, community-, and policy-level impact of a school-based cardiovascular risk detection screening program for children in underserved, rural areas: the CARDIAC Project. J Obes 2013;2013:732579.
34. Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: the CARDIAC project. Pediatrics 2010;126:260-5.
35. Johnson J, Giles RT, Larsen L, et al. Utah's Family High Risk Program: bridging the gap between genomics and public health. Prev Chronic Dis 2005;2(2):A24.
36. Centers for Disease Control and Prevention (CDC). Vital signs: avoidable deaths from heart disease, stroke and hypertensive disease - United States 2001-2010. MMWR Morb Mortal Wkly Rep 2013;62:721-7.
37. Healthy People 2020 web site. HealthyPeople.gov. Updated June 30, 2014. Accessed July 7, 2014.
38. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-S45.
39. Ademi Z, Watts GF, Juniper A, et al. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol 2013;167:2391-6.
40. Marks D, Wonderling D, Thorogood M, et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303.
41. Ned RM, Sijbrands EJ. Cascade screening for familial hypercholesterolemia (FH). PLoS Curr 2011;3. [RRN1238].
42. Stephenson SH, Larrinaga-Shum S, Hopkins PN. Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia. J Clin Lipidol 2009;3:94-100.